ATE119038T1 - Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt. - Google Patents

Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt.

Info

Publication number
ATE119038T1
ATE119038T1 AT89312875T AT89312875T ATE119038T1 AT E119038 T1 ATE119038 T1 AT E119038T1 AT 89312875 T AT89312875 T AT 89312875T AT 89312875 T AT89312875 T AT 89312875T AT E119038 T1 ATE119038 T1 AT E119038T1
Authority
AT
Austria
Prior art keywords
cataract
treatment
carboxylic acids
aliphatic
carbons
Prior art date
Application number
AT89312875T
Other languages
English (en)
Inventor
William H Garner
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE119038T1 publication Critical patent/ATE119038T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
AT89312875T 1988-12-09 1989-12-11 Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt. ATE119038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28276788A 1988-12-09 1988-12-09

Publications (1)

Publication Number Publication Date
ATE119038T1 true ATE119038T1 (de) 1995-03-15

Family

ID=23083041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89312875T ATE119038T1 (de) 1988-12-09 1989-12-11 Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt.

Country Status (6)

Country Link
US (1) US5399573A (de)
EP (1) EP0373002B1 (de)
JP (1) JPH02202818A (de)
AT (1) ATE119038T1 (de)
DE (1) DE68921436T2 (de)
ES (1) ES2068253T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE144142T1 (de) * 1991-01-10 1996-11-15 Transcend Therapeutics Inc Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
WO1995013827A1 (en) * 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5925658A (en) * 1995-03-02 1999-07-20 Sankyo Company, Limited Optically active thiazolidinone derivative
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5686450A (en) * 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
US5576278A (en) * 1995-06-07 1996-11-19 Alcon Laboratories, Inc. Stable liquid enzyme compositions and methods of use
WO1997035852A1 (en) * 1996-03-25 1997-10-02 Alcon Laboratories, Inc. Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
WO2017201318A1 (en) 2016-05-18 2017-11-23 Sound Pharmaceuticals Incorporated Treatment of meniere's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474817A (en) * 1980-02-29 1984-10-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4351826A (en) * 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4526789A (en) * 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
JPS5718615A (en) * 1980-07-07 1982-01-30 Senjiyu Seiyaku Kk Anticataract agent
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US5091421A (en) * 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors

Also Published As

Publication number Publication date
DE68921436T2 (de) 1995-08-10
EP0373002B1 (de) 1995-03-01
EP0373002A2 (de) 1990-06-13
DE68921436D1 (de) 1995-04-06
US5399573A (en) 1995-03-21
EP0373002A3 (de) 1991-07-31
JPH02202818A (ja) 1990-08-10
ES2068253T3 (es) 1995-04-16

Similar Documents

Publication Publication Date Title
ATE119038T1 (de) Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt.
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
TW206970B (de)
ES2012507A6 (es) Un procedimiento para la preparacion de derivados de b-lactama.
DE3750464D1 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
DK707988D0 (da) Fremgangsmaade til at haemme virus
NO833528L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklobutan-derivater
DE69019404T2 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
HUT50464A (en) Process for producing phenothiazin derivatives
NO169229C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-(3-alkyl-5-tert.butyl-4-hydroksyfenyl)-2-amino-6h-1,3,4-tiadiaziner
FR2539415B1 (fr) Derives de la d-2 imidazoline, leur preparation et leur application en therapeutique
IE44730L (en) Phenyl piperazines
ES2054829T3 (es) Antibioticos del grupo mureidomicina, su preparacion y su empleo.
FR2663026B1 (fr) Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
ATE135571T1 (de) Organogermaniumderivate enthaltende zubereitungen zur therapeutischen verwendung
ATE58141T1 (de) 1-hydroxy-5-oxo-5h-pyrido(3,2-a>-phenoxazin-3carbons|ureester.
NO167382C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-hydroxy-4-(substituerte alkenyl)cyklohexancarboxylsyrer.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties